ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects-Reference-Cited by-同舟云学术

ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects

Published:2014-02-10 Issue:3 Volume:124 Page:981-999
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Qiu Haiyan,Lee Sebum,Shang Yulei,Wang Wen-Yuan,Au Kin Fai,Kamiya Sherry,Barmada Sami J.,Finkbeiner Steven,Lui Hansen,Carlton Caitlin E.,Tang Amy A.,Oldham Michael C.,Wang Hejia,Shorter James,Filiano Anthony J.,Roberson Erik D.,Tourtellotte Warren G.,Chen Bin,Tsai Li-Huei,Huang Eric J.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference63 articles.

1. Mutations in the FUS/TLS Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis

2. Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6

3. Distinct pathological subtypes of FTLD-FUS

4. Extensive FUS-Immunoreactive Pathology in Juvenile Amyotrophic Lateral Sclerosis with Basophilic Inclusions

5. Male sterility and enhanced radiation sensitivity in TLS-/- mice

Cited by 234 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineered NLS-chimera downregulates expression of aggregation-prone endogenous FUS;Nature Communications;2024-09-10

2. Promising animal models for amyotrophic lateral sclerosis drug discovery: a comprehensive update;Expert Opinion on Drug Discovery;2024-08-08

3. Allele-Selective Thiomorpholino Antisense Oligonucleotides as a Therapeutic Approach for Fused-in-Sarcoma Amyotrophic Lateral Sclerosis;International Journal of Molecular Sciences;2024-08-03

4. The Current Landscape of Hypotheses Describing the Contribution of CD4+ Heterogeneous Populations to ALS;Current Issues in Molecular Biology;2024-07-23

5. Reversal of cognitive deficits in FUSR521G amyotrophic lateral sclerosis mice by arimoclomol and a class I histone deacetylase inhibitor independent of heat shock protein induction;Neurotherapeutics;2024-07